LeMaitre Vascular (LMAT)
(Real Time Quote from BATS)
$66.43 USD
+0.97 (1.48%)
Updated Apr 29, 2024 02:19 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LMAT 66.43 +0.97(1.48%)
Will LMAT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LMAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LMAT
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
Here's Why You Should Retain Medtronic (MDT) Stock for Now
LMAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
Here's Why You Should Add DaVita (DVA) to Your Portfolio
Other News for LMAT
Buy Rating Affirmed: LeMaitre Vascular’s Growth and Profitability Outlook
LeMaitre just upgraded at Stifel, here's why
Doubling Down On Telus In Smith Maneuver - March 2024 Dividend Income Report
LeMaitre Will Announce First Quarter 2024 Earnings Results May 2, 2024
Staar Surgical Co's Meteoric Rise: Unpacking the 52% Surge in Just 3 Months